Femasys Receives AMA CPT Editorial Panel Approval for New Category III CPT Code for FemaSeed Intratubal Insemination

Stock Information for PharmaCyte Biotech Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About PharmaCyte Biotech Inc.

Femasys Appoints Dr. Kenneth D. Eichenbaum to Board of Directors
Femasys Advances FemBloc Toward U.S. Approval with Initiation of Pivotal Trial Enrollment
Femasys Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Femasys Announces FemBloc® Permanent Birth Control Has Achieved MDSAP Certification, Advancing Global Market Access
Femasys Expands European Commercial Footprint with Swiss Partner for FemBloc, FemaSeed, and Portfolio Products
Femasys Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement
Femasys Announces Partnership with Refuah Health Center to Expand First-Line Access to FemaSeed® in Community-Based Care
Femasys Secures U.S. FDA Clearance for Next-Generation FemVue Diagnostic Device

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.